ClearPoint Neuro, Inc. (CLPT)

NASDAQ: CLPT · Real-Time Price · USD
29.60
+3.21 (12.16%)
At close: Oct 8, 2025, 4:00 PM EDT
30.01
+0.41 (1.40%)
After-hours: Oct 8, 2025, 7:59 PM EDT
12.16%
Market Cap841.45M
Revenue (ttm)33.59M
Net Income (ttm)-22.22M
Shares Out 28.43M
EPS (ttm)-0.80
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,336,091
Open26.66
Previous Close26.39
Day's Range26.01 - 29.87
52-Week Range9.76 - 29.87
Beta1.19
AnalystsStrong Buy
Price Target27.67 (-6.52%)
Earnings DateNov 6, 2025

About CLPT

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; li... [Read more]

Sector Healthcare
Founded 1998
Employees 115
Stock Exchange NASDAQ
Ticker Symbol CLPT
Full Company Profile

Financial Performance

In 2024, ClearPoint Neuro's revenue was $31.39 million, an increase of 31.04% compared to the previous year's $23.96 million. Losses were -$18.91 million, -14.37% less than in 2023.

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for CLPT stock is "Strong Buy." The 12-month stock price target is $27.67, which is a decrease of -6.52% from the latest price.

Price Target
$27.67
(-6.52% downside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

ClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los Angeles

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 7, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigatio...

1 day ago - Accesswire

ClearPoint Neuro Announces Expanded International Clearances for Key Therapy Delivery Product; Now Totaling 34 Countries Worldwide

The clearly established history across global regulatory bodies is expected to de-risk BioPharma partners' pathways towards achieving global scale and standardization. SOLANA BEACH, CALIFORNIA / ACCES...

2 days ago - Accesswire

ClearPoint Neuro: AMT-130 Highlights A Bright Future

ClearPoint's stock surged after uniQure announced strong Huntington's data, highlighting the value of its drug delivery platform. CLPT's technology has been validated by the AMT-130 data, positioning ...

6 days ago - Seeking Alpha

ClearPoint Neuro Announces Development and Demonstration of the Company's Proprietary Robotic Neuro-Navigation System

New Product Category Will Enable Added Flexibility to Support Commercial Launches of Cell and Gene Therapy SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 1, 2025 / ClearPoint Neuro, Inc. (Nasdaq...

7 days ago - Accesswire

ClearPoint Neuro: Selling The Tools For Brain Therapies

ClearPoint Neuro surged over 100% following positive Huntington's Disease data from partner uniQure, highlighting its drug delivery device's role in AMT-130 trials. CLPT's SmartFlow cannula is already...

13 days ago - Seeking Alpha

ClearPoint Neuro Announces the Appointment of Dr. Paul Larson as Chief Medical Officer

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / September 25, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise naviga...

13 days ago - Accesswire

ClearPoint Neuro Announces FDA Clearance Expanding Compatibility of the ClearPoint Prism Neuro Laser Therapy System with 1.5T MRI Scanners

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / September 4, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigat...

4 weeks ago - Accesswire

ClearPoint Neuro: Biopharma Momentum Continues To Build

ClearPoint Neuro's Q2 results were solid; although real upside is likely to be more apparent from 2026 onward. Key catalysts include the launch of GLP services and partner program commercialization, p...

7 weeks ago - Seeking Alpha

ClearPoint Neuro, Inc. (CLPT) Q2 2025 Earnings Call Transcript

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Joseph Michael Burnett - President, CEO & Director Danilo D'Alessandro - Chief Fi...

2 months ago - Seeking Alpha

ClearPoint Neuro Reports Second Quarter 2025 Results

Record Revenue and Substantial Cash Infusion Highlight the Company's ‘Fast. Forward.' Strategy SOLANA BEACH, CA / ACCESS Newswire / August 12, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company...

2 months ago - Accesswire

ClearPoint Neuro Announces Progression of Key Partner Milestones throughout the Global Biologics and Drug Delivery Portfolio

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / August 4, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to ...

2 months ago - Accesswire

ClearPoint Neuro to Announce Second Quarter 2025 Results August 12, 2025

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / July 23, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation ...

2 months ago - Accesswire

ClearPoint Neuro: Consumables Growth Is Promising

ClearPoint's fundamentals remain strong, despite recent stock weakness. Consumables growth and an expectation of 15-20 system placements in 2025 are illustrative of this strength. The introduction of ...

3 months ago - Seeking Alpha

I Missed The Quantum Rally - I Won't Miss The Next One

Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, progra...

5 months ago - Seeking Alpha

ClearPoint Neuro, Inc. (CLPT) Q1 2025 Earnings Call Transcript

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Joseph Burnett - President and Chief Executive Officer Danilo D'Alessandro - Chief F...

5 months ago - Seeking Alpha

ClearPoint Neuro Reports First Quarter 2025 Results

Record Revenue Highlighted by 70% Growth in Single-Use Navigation and Therapy Products SOLANA BEACH, CALIFORNIA / ACCESS Newswire / May 13, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"),...

5 months ago - Accesswire

ClearPoint Neuro Announces Investment of up to $110 Million by Oberland Capital with $33.5 Million Funded at Closing

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / May 12, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation t...

5 months ago - Accesswire

ClearPoint Neuro: Fundamentals Continue To Strengthen

ClearPoint continues to make progress in relation to its LITT and operating room expansion efforts. More importantly, ClearPoint's partners continue to provide positive news in relation to their thera...

5 months ago - Seeking Alpha

ClearPoint Neuro, Together with its Partner Clinical Laserthermia Systems, Announces FDA Submission to Expand the Labeling of ClearPoint Prism(R) to Include 1.5 T MRI

SOLANA BEACH, CA / ACCESS Newswire / April 28, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the ...

5 months ago - Accesswire

ClearPoint Neuro to Announce First Quarter 2025 Results May 13, 2025

SOLANA BEACH, CA / ACCESS Newswire / April 25, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the ...

5 months ago - Accesswire

ClearPoint Neuro Announces Full Market Release of ClearPoint Navigation Software Version 3.0 - Delivering the First End-to-End ClearPoint Navigation Solution to the Operating Room

The platform will be showcased at the American Academy of Neurological Surgeons Annual Meeting in Boston on April 25-28, 2025. SOLANA BEACH, CALIFORNIA / ACCESS Newswire / April 24, 2025 / ClearPoint ...

5 months ago - Accesswire

ClearPoint Neuro: Drug Delivery Prospects Continue To Strengthen

ClearPoint's Q4 results were soft, although lumpy growth should be expected given the nature of ClearPoint's business. Neurosurgery growth remains robust, and the expansion of preclinical and clinical...

7 months ago - Seeking Alpha

ClearPoint Neuro, Inc. (CLPT) Q4 2024 Earnings Call Transcript

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessandro - CFO Conference Call Participants Frank ...

8 months ago - Seeking Alpha

ClearPoint Neuro Reports Fourth Quarter and Full Year 2024 Results

Achieved Record Revenue for 2024 and Growth of 31%; Reduced 2024 Operational Cash Burn by 35% SOLANA BEACH, CALIFORNIA / ACCESS Newswire / February 26, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the...

8 months ago - Accesswire

ClearPoint Neuro to Announce Fourth Quarter and Full Year 2024 Results February 26, 2025

SOLANA BEACH, CA / ACCESS Newswire / February 14, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to t...

8 months ago - Accesswire